These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36792107)

  • 1. Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program.
    Deodhar A; Poddubnyy D; Rahman P; Ermann J; Tomita T; Bolce R; Leage SL; Kronbergs A; Johnson C; Araújo J; Leung A; van der Heijde D
    J Rheumatol; 2023 Aug; 50(8):1020-1028. PubMed ID: 36792107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
    Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
    Landewé RB; Gensler LS; Poddubnyy D; Rahman P; Hojnik M; Li X; Liu Leage S; Adams D; Carlier H; Van den Bosch F;
    Ann Rheum Dis; 2021 Aug; 80(8):1022-1030. PubMed ID: 33958326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
    Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
    Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
    Orbai AM; Gratacós J; Turkiewicz A; Hall S; Dokoupilova E; Combe B; Nash P; Gallo G; Bertram CC; Gellett AM; Sprabery AT; Birt J; Macpherson L; Geneus VJ; Constantin A
    Rheumatol Ther; 2021 Mar; 8(1):199-217. PubMed ID: 33278016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
    Braun J; Kiltz U; Deodhar A; Tomita T; Dougados M; Bolce R; Sandoval D; Lin CY; Walsh J
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35853675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.
    Zheng M; Chen X; Wang F; Chen J; Jackson K; Yang F; Payne C; Li H; Wang Y; Xiao Z; Zheng J
    Adv Ther; 2023 Sep; 40(9):3804-3816. PubMed ID: 37356077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
    van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
    Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.
    Landewé RBM; Poddubnyy D; Rahman P; Van den Bosch FE; Bolce R; Liu Leage S; Lisse JR; Park SY; Gensler L
    Ann Rheum Dis; 2023 Feb; 82(2):212-216. PubMed ID: 36100350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
    van der Horst-Bruinsma IE; de Vlam K; Walsh JA; Bolce R; Hunter T; Sandoval D; Zhu D; Geneus V; Soriano ER; Magrey M
    Adv Ther; 2022 Jun; 39(6):2806-2819. PubMed ID: 35429281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
    Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
    Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
    Maksymowych WP; Baraliakos X; Lambert RG; Landewé R; Sandoval D; Carlier H; Lisse J; Li X; Hojnik M; Østergaard M
    Lancet Rheumatol; 2022 Sep; 4(9):e626-e634. PubMed ID: 38288892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
    van der Heijde D; Østergaard M; Reveille JD; Baraliakos X; Kronbergs A; Sandoval DM; Li X; Carlier H; Adams DH; Maksymowych WP
    J Rheumatol; 2022 Mar; 49(3):265-273. PubMed ID: 34853086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
    Lebwohl MG; Gordon KB; Gallo G; Zhang L; Paul C
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):301-309. PubMed ID: 31479549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks.
    Marzo-Ortega H; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Dougados M; Combe B; Wei JC; Baraliakos X; Hunter T; Sandoval D; Li X; Zhu B; Bessette L; Deodhar A
    Rheumatol Ther; 2020 Dec; 7(4):759-774. PubMed ID: 32814997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
    Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies.
    Kiltz U; Wei JC; van der Heijde D; van den Bosch F; Walsh JA; Boonen A; Gensler LS; Hunter T; Carlier H; Dong Y; Li X; Bolce R; Strand V; Braun J
    J Rheumatol; 2021 Feb; 48(2):188-197. PubMed ID: 32669450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.